For over 25 years Dr. Rittenhouse-Olson , University of Buffalo (UB) laboratory has been involved in studying carbohydrate tumor associated antigens, and she has studied TF-Ag since 1985. Kate left her position as Professor and Director of the Biotechnology Program at the University of Buffalo to focus fully on bringing hJAA_F11 to the clinic. Most of the preclinical testing of this monoclonal antibody to the cancer target TF-Ag was performed under her direction. Dr. Rittenhouse-Olson’s training as an immunologist, and her ASCP certification as a specialist in clinical immunology, along with her research experience amply suits the needs for her role as President of For-Robin. She supervises all aspects of the work, at UB and at For-Robin. She is committed to bringing the promising JAA-F11 antibody to clinical trials. The FDA submission is underway. Kate's is co-author of a clinical immunology textbook, Contemporary Clinical Immunology and Serology. She can be reached at krolson@buffalo.edu